Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 11/20 | 0.42 |
| ▸ | RAMP1 | O60894 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506605 | 0.90 | CALCRL (0.48) | CALCRLRAMP1 | |
| SCHEMBL6503913 | 0.89 | CALCRL (0.45) | CALCRLRAMP1CTSS | |
| SCHEMBL6504866 | 0.88 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL12881781 | 0.88 | CALCRL (0.39) | CALCRLRAMP1CTSS | |
| SCHEMBL6504879 | 0.88 | CALCRL (0.50) | CALCRLRAMP1 | |
| SCHEMBL12881783 | 0.87 | CALCRL (0.40) | CALCRLRAMP1CTSS | |
| SCHEMBL14007772 | 0.87 | CALCRL (0.39) | CALCRLRAMP1CTSS | |
| SCHEMBL13046503 | 0.87 | CALCRL (0.37) | CALCRLRAMP1CTSS | |
| SCHEMBL6509426 | 0.86 | CALCRL (0.40) | CALCRLRAMP1CTSS | |
| SCHEMBL6509436 | 0.86 | CALCRL (0.40) | CALCRLRAMP1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280887-A1 | Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions | CALCRL, CALCR, BDKRB2 | CALCRL 1/4885RAMP1 63/4885CTSS 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.